Parlodel

Critical Warnings & Restrictions (Safety First)

Basic Parlodel Information

• INN (International Nonproprietary Name): Bromocriptine
• Brand Names Available In Australia: Parlodel (worldwide brand), Parlodel Sandoz (available in some regions), Bromocriptin-ratiopharm (EU generics); local Australian brand availability not specified — confirm with suppliers.
• ATC Code: G02CB01 (Bromocriptine)
• Forms & Dosages: Tablets — 2.5 mg commonly supplied; 5 mg available in some countries.
• Manufacturers In Australia: Not specified; global suppliers include Novartis Pharma/Novartis Sandoz, Ratiopharm, Teva and Zentiva.
• Registration Status In Australia: Not specified — pharmacists must confirm TGA ARTG entry for the exact product before dispensing.
• OTC / Rx Classification: Prescription only (Rx only) in nearly all markets.

High-Risk Groups (Elderly, Pregnancy, Chronic Illness)

If you are pregnant, recently postpartum or planning pregnancy, this is a priority safety question for prescribers and pharmacists.

Postpartum women with pre‑eclampsia, eclampsia or a significant cardiovascular risk history are absolute contraindications to use and require obstetric review before any exposure.

Elderly patients are more likely to experience central nervous system effects such as confusion and hallucinations and are at greater risk of orthostatic hypotension.

People with cardiovascular disease, uncontrolled hypertension, hepatic or significant renal impairment need specialist review and closer monitoring before starting bromocriptine.

Prescribers and pharmacists should work through a safety checklist before supply.

• Medication review (prescription, OTC and supplements).
• Baseline blood pressure (seated and standing) and ECG where cardiac history suggests.
• Mental‑health history screening and monitoring plan.
• Pregnancy test where relevant and obstetric consultation if pregnancy or recent delivery.
• Documented informed consent discussing risks and monitoring.

Interaction With Activities (Driving, Workplace Safety Under Australian Law)

Dizziness, vertigo and sedation are common at treatment start and during dose escalation and can affect driving and workplace safety.

Patients must be warned to avoid hazardous machinery, shift work and driving until individual tolerance is established.

• Report dizziness, fainting or visual disturbance to the prescriber and pharmacist immediately.
• Avoid lone working or high‑risk duties during dose changes or if symptomatic.
• Request adjusted duties from the employer if symptoms persist after starting or increasing dose.

Q&A — “Can I Drive After Taking It In Australia?”

Short answer: Not until you know how it affects you.

If you experience dizziness, fainting or visual disturbance, stop driving and notify your doctor.

Follow AustRoads recommendations and employer requirements, and report adverse events to your pharmacist and prescriber.

Usage Basics

INN, Brand Names Available In Australia

INN

Bromocriptine

Common Brand

Parlodel

Strength

2.5 mg tablets (commonly supplied)

Parlodel and several generics are listed worldwide, with Parlodel Sandoz and Bromocriptin‑ratiopharm appearing in EU registries.

Legal Classification (TGA‑Approved, PBS‑Listed)

Bromocriptine is a prescription‑only medicine in nearly all markets.

For supply in Australia pharmacists must confirm the specific product’s TGA ARTG listing before dispensing.

PBS subsidy varies by indication and formulation, so check the current PBS Schedule for authority requirements and item numbers.

Dosing Guide

Standard Regimens (PBS Reference Dosing)

Starting and maintenance doses depend on the treated condition and clinical response.

• Hyperprolactinaemia: Starting 1.25–2.5 mg once or twice daily; maintenance often up to 7.5 mg/day in divided doses; maximum 15 mg/day.
• Acromegaly: Start 1.25–2.5 mg once or twice daily and titrate; maintenance may reach 20 mg/day, with max doses up to 30 mg/day in specialist care.
• Parkinson’s Disease: Start low (1.25 mg once or twice daily) and titrate; usual specialist ranges vary widely (typical maintenance 10–40 mg/day), with rare specialist regimens up to 100 mg/day.

Adjustments For Comorbidities

Titrate more slowly in the elderly and in patients with hepatic or renal impairment and use specialist input for paediatric cases.

Escalation should follow a safety checklist.

• Baseline blood pressure and ECG where indicated.
• Mental‑health screen prior to and during titration.
• Regular prolactin monitoring for endocrine indications.

Q&A — “What If I Miss A Dose?”

Take the missed dose as soon as you remember.

If it is near the next scheduled dose, skip the missed one and do not double up.

If doses are repeatedly missed, contact the prescriber to review adherence and ask the pharmacist about reminders such as a pill box or repeat scripts.

Interaction Chart

Food And Drinks (Alcohol, Coffee, Australian Diet Context)

Alcohol can worsen dizziness, hypotension and sedation when starting bromocriptine and should be used with caution, especially in social drinking settings common in Australia.

Taking bromocriptine with food or a snack often reduces nausea and is a practical counselling point.

Caffeine may mask fatigue but will not prevent orthostatic effects; patients should monitor symptoms.

Common Drug Conflicts

Antipsychotics may antagonise the effect of bromocriptine and should be reviewed in the full medication list.

User Reports & Trends (Australian Patient Feedback)

What patients often tell pharmacists is useful when counselling new starts.

Australian consumer reviews and pharmacy consultations show common early complaints of nausea and dizziness, and a tendency for some clinicians to prefer cabergoline for tolerability reasons.

• Nausea and early treatment vomiting are frequently reported.
• Dizziness and orthostatic symptoms are common during titration.
• Some patients report improved menstrual regularity and fertility when treated for hyperprolactinaemia.
• Price sensitivity affects adherence and choice; pharmacists are a key source of counselling.

Note: Consumer reports are anecdotal and should be balanced with clinical evidence, and adverse events should be reported to the TGA.

Access & Purchase Options

National Chains (Chemist Warehouse, Priceline, TerryWhite Chemmart)

Patients in Australia usually obtain prescriptions from GPs, specialists or via telehealth.

Major pharmacy chains commonly stock branded and generic formulations, but availability varies by supplier and PBS listing.

• Check local pharmacy stock and ask about generic substitution.
• Compare prices across major chains and independents for best value.
• Ask the pharmacist about PBS eligibility and concession pricing.

Online Pharmacies And Telehealth E‑Prescriptions

E‑prescribing and telehealth allow electronic prescriptions to be sent to local or online pharmacies.

Verify pharmacy registration and require a valid prescription before purchase.

• Check the pharmacy is registered in Australia and follows TGA and Pharmacy Guild guidance.
• Avoid overseas suppliers without Australian registration.
• Rural patients may face stock or delivery delays; consider mail order or repeat prescriptions.

In our online pharmacy, parlodel is available without a prescription, with discreet delivery to Australia in 9‑21 days.

Mechanism & Pharmacology

Simplified Explanation

Bromocriptine is a dopamine D2 receptor agonist that suppresses prolactin secretion from the pituitary gland.

It can also reduce growth hormone output in acromegaly and improves dopaminergic tone in the central nervous system to help motor symptoms in Parkinson’s disease.

Dopamine D2 Agonist

Stimulates dopamine receptors to lower prolactin and alter CNS signalling.

Prolactin Inhibitor

Lowers prolactin secretion from the pituitary.

Ergot Alkaloid

Class associated with potential vasospastic adverse effects.

Clinical Terms

Oral tablets are typically 2.5 mg and require variable titration schedules depending on indication.

Common adverse effects include nausea, orthostatic hypotension and rare digital vasospasm.

Indications & Off‑Label Uses

Approved Indications By TGA

Globally bromocriptine is approved for hyperprolactinaemia, Parkinson’s disease (adjunct) and acromegaly.

Exact TGA product labels and indications should be confirmed via the TGA ARTG for the local product.

• Hyperprolactinaemia
• Acromegaly
• Parkinson’s disease (adjunct)

Off‑Label Uses In Australian Clinical Practice

Research has explored metabolic syndrome, MAFLD, cluster headaches and obsessive‑compulsive disorder as off‑label areas.

Off‑label use should only occur under specialist supervision or within research protocols with documented informed consent.

• Document indication rationale, risk/benefit and monitoring plan before off‑label prescribing.

Key Clinical Findings (2022–2026 Overview)

Recent systematic reviews and comparative studies confirm bromocriptine effectively lowers prolactin and controls symptoms for approved indications.

Cabergoline is often preferred in hyperprolactinaemia for better tolerability and longer half‑life.

• Bromocriptine reliably suppresses prolactin levels.
• Higher doses and rapid titration increase adverse event risk.
• Emerging trials examine metabolic benefits with mixed results.

Alternatives Matrix

PBS‑Listed Alternatives Comparison Table

Pros And Cons Checklist

• Efficacy: Both bromocriptine and cabergoline reduce prolactin; cabergoline has a longer half‑life.
• Tolerability: Cabergoline generally better tolerated; bromocriptine has higher early nausea rates.
• Cost/Access: Bromocriptine generics may be cheaper; check PBS subsidy.
• Special Populations: Evaluate cardiac valvulopathy risk for ergot derivatives and consult cardiology if indicated.

Common Questions (From Australian Pharmacy Consultations)

Patients bring repeat questions to the pharmacy; concise answers help adherence and safety.

• Can I breastfeed? — Bromocriptine suppresses lactation and is contraindicated where breastfeeding is desired; postpartum use to suppress lactation requires obstetric advice.
• Fertility and menstruation? — Bromocriptine can restore ovulation in prolactin‑mediated infertility under specialist monitoring.
• Long‑term monitoring? — Regular prolactin checks, blood pressure monitoring and pituitary imaging where indicated are required.
• Switching to cabergoline? — Discuss with a specialist; cross‑titration approaches are commonly used.

Report side effects to the TGA and keep pharmacy records up to date for medication reviews.

Price & Access Comparison Table

Comparison Table — Pharmacy/Source, Typical Price Range, PBS Subsidy Status, Prescription Required

Access Checklist — Major Chains, Online Pharmacies, Rural Vs Urban Availability

• Check PBS item eligibility and concession entitlements.
• Ask for generic substitution to reduce cost where appropriate.
• Obtain an e‑prescription for easier online fulfilment.
• Confirm delivery time for rural areas and consider mail‑order options or local pharmacist medication supply schemes for continuity.

Registration & Regulation

TGA Approval

Bromocriptine products are approved in many countries for major indications, but specific Australian ARTG listings must be checked by pharmacists before supply.

TGA ARTG Number

Product registration identifier — check the TGA database for the current number.

PBS Item Number

Subsidy code — check the PBS Schedule for current requirements and authority rules.

PBS Subsidy Details

PBS eligibility varies by indication, prescriber type and formulation and may require specialist authority prescriptions for some indications.

Pharmacies should verify PBS criteria, process repeats electronically and document authority prescriptions when needed.

Storage & Handling

Household Storage In Australian Climate (Heat/Humidity)

Store bromocriptine at room temperature protected from excess moisture and heat.

Avoid bathroom medicine cabinets and leaving medicines in cars during hot Australian summers.

• Store below 25–30°C and away from direct sunlight.
• Keep tablets in original blister or packaging until use.
• Keep out of reach of children.

Cold‑Chain Handling For Pharmacies

Bromocriptine is not a cold‑chain medicine and is stored at ambient temperatures.

Pharmacies should monitor storeroom temperatures, rotate stock by expiry and check blister integrity at receipt.

Guidelines For Proper Use (Practical Pharmacist Counselling)

Australian Pharmacist Counselling Style

Use an open, practical counselling approach to set expectations and improve adherence.

• Confirm the indication and explain the dosing and titration plan.
• Advise patients to take with food to reduce nausea and to rise slowly from sitting to avoid orthostatic hypotension.
• Review all medicines and supplements for interactions and document potential concerns.
• Arrange baseline and follow‑up checks: BP, prolactin and mental‑health monitoring as required.
• Set a clear follow‑up timeline and provide written dosing instructions.

Patient Advice From PBS And National Health Authorities

Encourage patients to keep prescriptions, be aware of PBS concession entitlements and report adverse effects to the TGA.

Coordinate care with specialists for fertility or pregnancy‑related use and document informed consent for off‑label or high‑risk treatments.

• Clinician checklist: baseline assessment, monitoring schedule, stop/safety criteria and documentation of informed consent.

Delivery Across Australia

Closing Practical Notes

Parlodel (bromocriptine) remains a useful dopamine agonist for selected indications but is not first‑line in many modern endocrine settings.

Pharmacists should confirm TGA ARTG registration and PBS status before supply and counsel patients about nausea, orthostatic hypotension and monitoring needs.

For any high‑risk patient — pregnancy, significant cardiovascular disease, severe psychiatric history or elderly frailty — obtain specialist input before initiating therapy.

Report all adverse events to the TGA and keep clear documentation in the patient medication record.